{"data":{"id":"10.6084/m9.figshare.1285024.v1","type":"dois","attributes":{"doi":"10.6084/m9.figshare.1285024.v1","prefix":"10.6084","suffix":"m9.figshare.1285024.v1","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Catania, Chiara","nameType":"Personal","givenName":"Chiara","familyName":"Catania","affiliation":[],"nameIdentifiers":[]},{"name":"Maur, Michela","nameType":"Personal","givenName":"Michela","familyName":"Maur","affiliation":[],"nameIdentifiers":[]},{"name":"Berardi, Rossana","nameType":"Personal","givenName":"Rossana","familyName":"Berardi","affiliation":[],"nameIdentifiers":[]},{"name":"Rocca, Andrea","nameType":"Personal","givenName":"Andrea","familyName":"Rocca","affiliation":[],"nameIdentifiers":[]},{"name":"Giacomo, Anna Maria Di","nameType":"Personal","givenName":"Anna Maria Di","familyName":"Giacomo","affiliation":[],"nameIdentifiers":[]},{"name":"Spitaleri, Gianluca","nameType":"Personal","givenName":"Gianluca","familyName":"Spitaleri","affiliation":[],"nameIdentifiers":[]},{"name":"Masini, Cristina","nameType":"Personal","givenName":"Cristina","familyName":"Masini","affiliation":[],"nameIdentifiers":[]},{"name":"Pierantoni, Chiara","nameType":"Personal","givenName":"Chiara","familyName":"Pierantoni","affiliation":[],"nameIdentifiers":[]},{"name":"Reinerio González-Iglesias","affiliation":[],"nameIdentifiers":[]},{"name":"Zigon, Giulia","nameType":"Personal","givenName":"Giulia","familyName":"Zigon","affiliation":[],"nameIdentifiers":[]},{"name":"Annaelisa Tasciotti","affiliation":[],"nameIdentifiers":[]},{"name":"Giovannoni, Leonardo","nameType":"Personal","givenName":"Leonardo","familyName":"Giovannoni","affiliation":[],"nameIdentifiers":[]},{"name":"Lovato, Valeria","nameType":"Personal","givenName":"Valeria","familyName":"Lovato","affiliation":[],"nameIdentifiers":[]},{"name":"Elia, Giuliano","nameType":"Personal","givenName":"Giuliano","familyName":"Elia","affiliation":[],"nameIdentifiers":[]},{"name":"Menssen, Hans D","nameType":"Personal","givenName":"Hans D","familyName":"Menssen","affiliation":[],"nameIdentifiers":[]},{"name":"Neri, Dario","nameType":"Personal","givenName":"Dario","familyName":"Neri","affiliation":[],"nameIdentifiers":[]},{"name":"Cascinu, Stefano","nameType":"Personal","givenName":"Stefano","familyName":"Cascinu","affiliation":[],"nameIdentifiers":[]},{"name":"Conte, Pier Franco","nameType":"Personal","givenName":"Pier Franco","familyName":"Conte","affiliation":[],"nameIdentifiers":[]},{"name":"Braud, Filippo De","nameType":"Personal","givenName":"Filippo De","familyName":"Braud","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"The tumour-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumours and expansion into patients with metastatic breast cancer"}],"publisher":"Taylor \u0026 Francis","container":{},"publicationYear":2015,"subjects":[{"subject":"60506 Virology","subjectScheme":"FOR"},{"subject":"FOS: Biological sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Biological sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"110309 Infectious Diseases","subjectScheme":"FOR"},{"subject":"FOS: Health sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Health sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Hematology"},{"subject":"Cancer"},{"subject":"Biological Sciences"},{"subject":"Immunology"},{"subject":"FOS: Clinical medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Clinical medicine","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Chemistry"},{"subject":"Pharmacology"},{"subject":"Medicine"},{"subject":"Biochemistry"}],"contributors":[],"dates":[{"date":"2015-01-02","dateType":"Created"},{"date":"2016-01-19","dateType":"Updated"},{"date":"2015","dateType":"Issued"}],"language":null,"types":{"ris":"DATA","bibtex":"misc","citeproc":"dataset","schemaOrg":"Dataset","resourceType":"Dataset","resourceTypeGeneral":"Dataset"},"relatedIdentifiers":[{"relationType":"IsSupplementTo","relatedIdentifier":"10.4161/19336918.2014.983785","relatedIdentifierType":"DOI"},{"relationType":"IsPreviousVersionOf","relatedIdentifier":"10.6084/m9.figshare.1285024","relatedIdentifierType":"DOI"}],"relatedItems":[],"sizes":["44052850 Bytes"],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":".A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efficacy of F16-IL2, a recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumours (phase Ib) and metastatic breast cancer (phase II).Six patient cohorts with progressive solid tumours (n = 19) received escalating doses of F16-IL2 [5-25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of doxorubicin (0-25mg/m\u003csup\u003e2\u003c/sup\u003e) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n = 10) received the drug combination at the RD. Clinical data and laboratory findings were analysed for safety, tolerability, and activity.F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25mg/m\u003csup\u003e2\u003c/sup\u003e). No human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively.Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67% disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks), considering 14 and 9 patients evaluable for efficacy. One patient experienced a long lasting partial response (45 weeks), still on-going at exit of study.F16-IL2 can be safely and repeatedly administered at the RD of 25 Mio I.U. in combination with 25mg/m\u003csup\u003e2\u003c/sup\u003e doxorubicin; its safety and activity are currently being investigated in combination with other chemotherapeutics, in order to establish optimal therapy settings.","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"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","url":"https://tandf.figshare.com/articles/dataset/The_tumour_targeting_immunocytokine_F16_IL2_in_combination_with_doxorubicin_dose_escalation_in_patients_with_advanced_solid_tumours_and_expansion_into_patients_with_metastatic_breast_cancer/1285024/1","contentUrl":null,"metadataVersion":3,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2016-01-19T13:05:50.000Z","registered":"2016-01-19T13:05:51.000Z","published":"2015","updated":"2020-09-04T19:39:53.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.1285024.v1","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}